Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03013010 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy(PREACT) | completed | Phase 3 | 204 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Dec 8, 2025 |
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)(FRUTIGA) | completed | Phase 3 | 703 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | active not recruiting | Phase 2 / Phase 3 | 201 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT06793917 | Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 269 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 20, 2025 | clinicaltrials |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.(PERISCOPEII) | active not recruiting | Phase 3 | 102 | The Netherlands Cancer InstituteOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06949033 | Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 668 | Zuoyi JiaoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT01815853 | Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer(Neo-CRAG) | completed | Phase 3 | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06939439 | Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | active not recruiting | Phase 3 | 416 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 3 | 616 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06755554 | Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer(ICGastr) | recruiting | Phase 3 | 105 | Ukrainian Society of Clinical OncologyOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 | clinicaltrials |
| NCT02112214 | Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population(HELPER) | active not recruiting | Phase 3 | 5,224 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04214990 | Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients(EASTERN) | recruiting | Phase 3 | 1,700 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02867839 | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer(RESCUE-GC) | terminated | Phase 3 | 29 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06296706 | A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | recruiting | Phase 3 | 630 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT02578368 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(FLOT5) | completed | Phase 3 | 183 | Krankenhaus NordwestOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04447352 | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)(PREVENT) | recruiting | Phase 3 | 200 | Krankenhaus NordwestOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06608381 | Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10) | recruiting | Phase 3 | 440 | Gangnam Severance HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT02845479 | The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I(POISE) | completed | Phase 3 | 22 | The Canadian College of Naturopathic MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00400179 | A Safety and Efficacy Study in Patients With Gastric Cancer | completed | Phase 3 | 1,053 | Taiho Oncology, Inc.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT01285557 | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial(DIGEST) | terminated | Phase 3 | 361 | Taiho Oncology, Inc.INDUSTRY | 20 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT01839773 | Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer(DREAM) | completed | Phase 3 | 238 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06313567 | Metronomic Capecitabine in Stage III Gastric Cancer | recruiting | Phase 3 | 722 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06161207 | 3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer(3D-4K-ICG) | recruiting | Phase 3 | 702 | Fujian Medical UniversityOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT02267343 | Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer | completed | Phase 3 | 493 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT02746796 | Study of ONO-4538 in Gastric Cancer | completed | Phase 2 / Phase 3 | 680 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT03006705 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | completed | Phase 3 | 800 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 4 | May 3, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | completed | Phase 3 | 525 | AstraZenecaINDUSTRY | 4 | Mar 22, 2024 | clinicaltrials |
| NCT04597294 | Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence(CHIMERA) | recruiting | Phase 3 | 600 | Jagiellonian UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT01917552 | Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS | unknown | Phase 3 | 870 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT01935778 | Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH | recruiting | Phase 3 | 286 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | unknown | Phase 3 | 351 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2025source: clinicaltrials